Neurogene Financial Ratios
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.40-0.10 (-0.38%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurogene ratio analysis
Return on equity reached -34.1%, meaning Neurogene generated -0.34 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Neurogene financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | — | 441.17 | — | — | — | — | — | 45.72 | — | — |
| Price / book | 1.62 | 1.31 | — | — | — | 76.43 | 41.40 | 15.73 | 55.78 | 43.13 |
| Operating margin | — | -8,930.3% | — | — | — | — | — | -130.5% | — | — |
| Net margin | — | -8,123.7% | — | — | — | — | — | -126.3% | — | — |
| Free cash flow margin | — | -7,720.1% | — | — | — | — | — | -126.5% | — | — |
| Return on equity (ROE) | -34.1% | -24.2% | -19.5% | — | — | -17.4% | -49.0% | -43.5% | -50.7% | -25.6% |
| Return on assets (ROA) | -31.3% | -22.4% | -16.3% | -50.5% | -37.2% | -15.8% | -47.2% | -40.7% | -45.5% | -24.0% |
| Current ratio | 16.56 | 20.84 | 8.72 | 12.74 | 16.67 | 24.66 | 30.28 | 16.68 | 9.93 | 10.87 |
| Revenue growth | -100.0% | — | — | — | — | — | — | — | — | — |